Related Experiment Videos
The ten most commonly asked questions about stroke prevention in atrial fibrillation
1The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York 10029-6574, USA.
Cardiology in Review
|July 24, 2001
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.
Journal of thrombosis and haemostasis : JTH·2015
A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
Journal of thrombosis and haemostasis : JTH·2015
Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation.
International journal of clinical practice·2015
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
Journal of clinical pharmacology·2014
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach.
Journal of thrombosis and haemostasis : JTH·2013
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.
Journal of thrombosis and haemostasis : JTH·2010
The Ischemia-Plaque Paradox: A Mechanistic Framework for Chronic Coronary Syndromes.
Cardiology in review·2026
Scabies Treatment Failure: Beyond Drug Resistance and Toward a Multidimensional Understanding.
Journal of tropical medicine·2026
Assessment of Healthcare Workers' Understanding of PLHIV's Rights Based on the Framework of HIV and AIDS Act 2017 in India.
Journal of the International Association of Providers of AIDS Care·2026